Lithium Citrate
(Synonyms: 柠檬酸四锂盐,Litarex) 目录号 : GC11127
柠檬酸锂 (Litarex) 四水合物是藤黄果的主要活性成分。
Cas No.:6080-58-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Lithium Citrate is the active component of Lithium which is a drug used in treatment of psychiatric disease [1].
Lithium Citrate has shown the effects on metabolic and signaling pathways in the brain based on the specific clinical condition and disease model [2]. Lithium Citrate has been reported to use as a mood stabilizer when treating bipolar mood disorders (BD) and reduce the risk of self-harm in BD patient. In addition, Lithium Citrate has been found to be the choice drug in treatment of acute manic episodes. Moreover, Lithium Citrate has been revealed to dissolve uric acid crystals in urine obtained from patients with gout. Besides, Lithium Citrate has been exhibited to have some dose-dependent side-effects. The most of the side-effects of Lithium Citrate is the tendency to inhibit the prostatic acid phosphatase enzyme (PAP), which leading to the accumulation of PAP [1].
References:
[1] Oruch R1, Elderbi MA2, Khattab HA3, Pryme IF4, Lund A5. Lithium: A review of pharmacology, clinical uses, and toxicity. Eur J Pharmacol. 2014 Jun 30. pii: S0014-2999(14)00493-2.
[2] Janson CG1, Assadi M, Francis J, Bilaniuk L, Shera D, Leone P.Lithium citrate for Canavan disease. Pediatr Neurol. 2005 Oct; 33(4):235-43.
| Cas No. | 6080-58-6 | SDF | |
| 别名 | 柠檬酸四锂盐,Litarex | ||
| 化学名 | trilithium;2-hydroxypropane-1,2,3-tricarboxylate;tetrahydrate | ||
| Canonical SMILES | [Li+].[Li+].[Li+].C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.O.O.O.O | ||
| 分子式 | C6H5O7.4H2O.3Li | 分子量 | 281.98 |
| 溶解度 | ≥ 14.1mg/mL in DMSO with ultrasonic and warming | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5464 mL | 17.7318 mL | 35.4635 mL |
| 5 mM | 0.7093 mL | 3.5464 mL | 7.0927 mL |
| 10 mM | 0.3546 mL | 1.7732 mL | 3.5464 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。